Healthcare AI: De-Risking Failure Modes for Investors
The promise of artificial intelligence in healthcare is transformative, yet the landscape is littered with cautionary tales, stark reminders that innovation without robust validation can…
Healthcare AI’s Billion Dollar Graveyard: The Evidence Gap
The echoes of Theranos’ spectacular collapse still reverberate through healthcare, a stark reminder of the perils of hype over evidence. Yet, the investment community continues…
Tempus AI: De-Risking a Billion Dollar Data Platform
The burgeoning valuation of Tempus AI, reportedly reaching approximately $8.41 billion, underscores the immense investor confidence in platforms that integrate vast datasets with artificial intelligence…
Proteus Digital: The Unswallowed Pill & AI’s Human Hurdle
The promise of AI in healthcare often conjures images of precision diagnostics and personalized therapies, yet the path to real-world impact is fraught with challenges…
Cardiac AI: Data Provenance, Bias, and Billion Dollar Safety
The promise of artificial intelligence in healthcare is immense, yet its responsible deployment hinges on a critical, often overlooked, factor: the provenance of its training…
Akili: FDA Win, Commercial Fail. What Investors Missed.
The story of Akili Interactive, once hailed as a pioneer for its FDA-cleared video game therapy, and its subsequent workforce reductions and eventual acquisition, presents…
AI vs. MDs: The Accuracy Showdown Across 10 Specialties
The burgeoning integration of artificial intelligence into healthcare promises unprecedented advancements, yet it simultaneously casts a long shadow of concern regarding algorithmic safety. As clinicians…
The Billion Dollar Graveyard: AI’s Clinical Validation Crisis
The promise of artificial intelligence in healthcare is transformative, yet a sobering reality exists beneath the hype: a graveyard of once-lauded companies, representing over $62…